Axsome Therapeutics (AXSM) is trading higher as investors reposition ahead of a key late-April regulatory catalyst, amplified by recent analyst target increases. Guggenheim raised its AXSM price target to $245 from $220 while keeping a Buy rating, and increased its estimated probability of FDA approval for AXS-05 (Auvelity) in Alzheimer’s disease agitation to 85% (from 75%). (investing.com)

The central driver is the FDA’s scheduled action date of April 30, 2026 for Axsome’s supplemental filing for AXS-05 in Alzheimer’s disease agitation. The market is treating the decision as a binary event with meaningful valuation sensitivity because Alzheimer’s agitation would materially expand Auvelity’s addressable market and shift the company’s long-term revenue trajectory. (finance.yahoo.com)

With the decision date approaching, incremental changes in perceived approval probability can drive meaningful moves in biotech equities. Guggenheim outlined a framework where approval could push the stock above $200, while a negative decision could drive a move toward roughly $120–$125, underscoring why traders are reacting to updated Street math even without a new company press release today. (investing.com)

Near-term, investors will watch for any FDA-related updates ahead of April 30 and for sentiment shifts in sell-side notes as the event window tightens. The next scheduled corporate checkpoint is the next earnings report, listed for May 11, 2026, which could provide updated commercialization cadence and spending context ahead of potential launch preparations. (investing.com)